What were Gilead's main revenue drivers in 2004?

Gilead's primary revenue drivers in 2004 were its HIV products, including Viread, Emtriva, and Truvada, which collectively accounted for 73% of total product sales. AmBisome, an antifungal medication, also contributed significantly.

What is the significance of the Bristol-Myers Squibb collaboration?

The collaboration with Bristol-Myers Squibb (BMS) is a significant strategic move to develop and commercialize a fixed-dose combination of Gilead's Truvada and BMS's Sustiva. This joint venture aims to create a once-daily, single-pill HIV treatment regimen, which could simplify therapy for patients and potentially capture a larger market share.

How did Gilead manage its inventory and distribution channels in 2004?

To address previous sales volatility caused by wholesaler inventory fluctuations, Gilead implemented inventory management agreements (IMAs) with its three major U.S. wholesalers in July 2004. These agreements aim to align wholesaler purchasing with actual customer demand and limit speculative buying.

What are the key risks highlighted in the 10-K filing?

Key risks include heavy reliance on a limited number of products (HIV drugs and AmBisome) for revenue, intense competition from larger pharmaceutical companies, potential safety issues with marketed products, and the complex regulatory environment governing drug approvals and manufacturing. Additionally, patent expirations and the introduction of generic drugs pose future challenges.

GILD 10-K FY2004 Annual Report — Revenue, Net Income, EPS

Summary

Gilead Sciences, Inc. (GILD) demonstrated strong growth in 2004, with total revenues reaching $1.32 billion, a significant increase from the previous year, driven primarily by its HIV product portfolio. The company's flagship HIV drugs, Viread, Emtriva, and the newly launched Truvada, collectively accounted for 73% of total product sales. Viread, in particular, showed robust performance with a 38% year-over-year revenue increase. Beyond its core HIV business, Gilead also maintained stable revenues for AmBisome, its antifungal treatment, despite increasing competition. The company is actively pursuing growth through strategic initiatives, including product acquisitions, in-licensing, and collaborations, such as the significant joint venture with Bristol-Myers Squibb to develop a once-daily HIV combination therapy. Gilead's financial health appears strong, with substantial cash reserves and positive operating cash flows, positioning it well for continued investment in research and development and potential future product launches.

Key Highlights

1Total revenues grew to $1.32 billion in 2004, up from $867.9 million in 2003, representing substantial year-over-year growth.

2The HIV product portfolio (Viread, Emtriva, Truvada) was the primary revenue driver, accounting for 73% of total product sales and showing strong year-over-year growth.

3Truvada, a fixed-dose combination of Emtriva and Viread, was launched in the US in August 2004 and received EU approval in February 2005, signaling future growth potential.

4Gilead established a significant joint venture with Bristol-Myers Squibb in December 2004 to develop and commercialize a fixed-dose combination of Truvada and BMS's Sustiva.

5AmBisome sales remained stable, contributing 17% of total product sales, demonstrating resilience in a competitive market.

6The company ended 2004 with $1.25 billion in cash, cash equivalents, and marketable securities, indicating a strong liquidity position.

7Research and development expenses increased to $223.6 million in 2004, reflecting ongoing investment in new therapies, particularly for Hepatitis C (HCV).

GILEAD SCIENCES, INC. Annual Report, Year Ended Dec 31, 2004

Summary

Key Highlights

Frequently Asked Questions